Finding predictors of the response to antidepressant therapy is a major goal of molecular psychiatry. The genes encoding the serotonin (SERT) and dopamine (DAT1) transporters are among the possible candidate genes modulating an individual's antidepressant response. In a naturalistic prospective cohort study with a total of 190 fully assessed patients, improvement of depression symptoms during the 3 weeks following initiation of antidepressant therapy was recorded using the 21-item Hamilton Depression Rating Scale (HDRS). The SLC6A3 3 0 UTR 40-bp variable number of tandem repeats (VNTR) and the SLC6A4 5 0 44-bp insertion/deletion polymorphism were analyzed by polymerase chain reaction. There was a significantly smaller number of rapid responders among homozygous carriers of the DAT1 9-repeat allele (9/9) than among heterozygous (9/10) and homozygous (10/10) carriers of the 10-repeat allele (19 versus 37 versus 52%, respectively, P ¼ 0.0037). Median decline in HDRS score was 35, 40, and 52% in patients with the 9/9, 9/10, and 10/10 genotypes, respectively (P ¼ 0.013). The effect was found in all classes of medications (selective serotonin reuptake inhibitors (SSRIs), tricyclics, mirtazapine, venlafaxine) and statistically significant also within the subgroup of patients having received SSRIs. The serotonin promoter insertion/deletion genotype had no effect in the entire study group, but there was an insignificant trend of better response in the l/l and l/s carriers who received SSRIs or mirtazapine. In conclusion, the dopamine transporter VNTR polymorphism influenced rapid response to antidepressant therapy. Compared with homozygous carriers of the 10-repeat allele, carriers of the 9/10 genotype had an odds ratio (OR) calculated by logistic regression analysis of 1.6 (95% CI 0.8-3.2) and carriers of the 9/9 genotype had an OR of 6.0 (1.5-24.4) for no or poor response. Further studies are required to confirm this clinical association and to elucidate the underlying mechanisms.
Introduction
Search for valid molecular markers predicting the response to antidepressant drugs is a major goal of molecular psychiatry. Polymorphisms that modulate pharmacokinetics may play a role, but their power to distinguish responders from nonresponders is apparently only limited. 1 Several studies indicated that a 44-bp variable number of tandem repeats (VNTR) polymorphism in the promoter region of the gene encoding the high-affinity serotonin transporter (SERT) is related to antidepressant response. [2] [3] [4] [5] Besides serotonin and adrenergic substances, dopamine may also play an important role in depression and in antidepressant drug response. Lower dopamine concentrations were measured in CSF of depressed patients. 6 Dopamine transporter affinity measured with SPECT in the basal ganglia was higher in depressed patients than in healthy controls, indicating a diminished synaptic dopamine concentration. 7 Dopamine transporter (DAT1) activities were also found to be modulated by selective serotonin reuptake inhibitors (SSRIs), and extracellular striatal dopamine concentrations were reduced during medication with SSRIs. [8] [9] [10] A VNTR polymorphism in the 3 0 -untranslated region of gene SLC6A3 encoding the high-affinity dopamine transporter DAT1 was shown to be associated with various psychiatric phenotypes. 11 Its linkage to bipolar affective disorder has been suggested. 12, 13 Levels of DAT1 expression were higher in carriers of the 10-repeat allele than in carriers of the 9-repeat allele.
14 Reporter-gene assays, however, led to equivocal results: whereas some authors reported higher luciferase expression in cells transfected with the 10-repeat allele, 15, 16 these findings could not be corroborated by others. 12, 14 The reason for these discrepancies might be an incomplete linkage of the VNTR with transcriptionally relevant polymorphisms. 17 In this study, we analyzed whether antidepressant response was influenced by DAT1 40-bp variable number tandem repeats genotypes. In addition, the SERT 44 bp insertion/deletion polymorphism was analyzed as a potentially confounding variable.
Methods

Clinical study
Two-hundred and sixty-four unselected Caucasian patients of North-European origin suffering from major depression and newly admitted to several psychiatric hospitals in the central area of Berlin, Germany, were included. Diagnosis of major depression was confirmed by the Mini International Neuropsychiatric Interview (MINI), a structured diagnostic interview developed and validated for DSM-IV and ICD-10 psychiatric diagnosis. 18 Severity of depression was assessed by the 21-item Hamilton Depression Rating Scale (HDRS) and by the Clinical Global Impression scale (CGI). Inclusion criteria were hospitalization because of major depression (acute episode of major depression, DSM IV 296.2, 296.3, bipolar affective disorder I and II 296.5, 296.89, unspecified depressive disorder 311, 296.80, adjustment disorder with depressed mood 309.0). Diagnosis of depression had to be confirmed according to the MINI and according to the HDRS (at least 8 points). Patients were excluded from the study of their age was less than 18 years, if they had Asian or African ethnicity, if they were unable to give informed consent, if their depressive symptoms did not reach the criteria for major depression (HDRS o8 at admission to the hospital) or if depression was coincident with personality disorders or substance or alcohol abuse, organic mental disorder.
All raters were trained in HDRS rating and regular interrater meetings have been performed in order to achieve reduction of inter-rater variability. All investigators also used a detailed printed instruction how to perform the HDRS rating.
The study period covered the first 3 weeks following start of antidepressant medication. Patients were treated with antidepressant drugs, the common clinical regimen of regular talks, psychotherapeutic interviews, occupational therapy, and some forms of group therapy. Hamilton Depression Rating Scale rating was performed on days 1 and 21. Response was measured as percent decrease in HDRS and assigned to the antidepressant drug given in minimum 1 week prior to day 21. The study was approved by the ethics committee of the Charité University Medical Centre of the Humboldt University. All patients gave their written informed consent to participate in the study.
Genotyping
Genomic DNA was obtained from whole blood using automatized DNA-extraction procedures based upon binding to magnetic particles (Magne Pure s , Roche, Mannheim, Germany). Genotyping was performed using polymerase chain reaction (PCR) and analysis of restriction fragment length polymorphisms (RFLP) with the methods described earlier. 19 In short, for PCR amplification, 3 ml of undiluted genomic DNA were added to 22 ml reaction mix containing 1 Â PCR buffer II (Applied Biosystems, Foster City, CA, USA), 2.5 mM MgCl 2 , 140 mM dNTPs, 0.2 mM of the primers DAT1-f (5 0 -TGTGGTGTAGGGAACCGCCTGAGA-3 0 ) and DAT1-r (5 0 -TGTTGGTCTGCAGGCTGCCTGCAT-3 0 ), and 1 U of the Biotherm DNA polymerase (Rapidozym, Berlin, Germany). Polymerase chain reaction was performed under the following conditions: initial denaturation at 941C for 4 min, 35 cycles of 1 min at 931C, 1 min at 721C and a terminal extension for 7 min at 71C. Products were separated on 3% agarose gels. Their sizes varied from 324 to 564 bp representing six to 12 copies of the analyzed VNTR (324 bp ¼ 6 repeats, 404 bp ¼ 8 repeats, 444 bp ¼ 9 repeats, 484 bp ¼ 10 repeats, 524 bp ¼ 11 repeats, 564 bp ¼ 12 repeats).
The insertion/deletion polymorphism localized about 1 kb upstream the transcription initiation site of SLC6A4, the gene encoding the high-affinity SERT was genotyped as described earlier using 5 0 -GGCGTTGCCGCTCTGAATGC-3 0 as forward primer and 5 0 -GAGGGACTGAGCTGGACAAC CAC-3 0 as reverse primer. 20 
Statistical analysis
As primary parameter of response, reduction in HDRS during 3 weeks of treatment was calculated as (HDRS 1 -HDRS 21 )/ HDRS 1 *100, with HDRS 1 and HDRS 21 being the total score of the 21-item HDRS at day 1 (baseline) and day 21, respectively. 21 Response was defined as a decrease in HDRS of more than 50%, according to the World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. 22 The number of responders in dependence of genotypes was calculated as secondary response parameter.
The nonparametric Kruskal-Wallis test was used to test for differences between groups of unrelated subjects. If there was good a priori evidence for trends, the nonparametric Jonckheere-Terpstra trend test was applied. 23 The latter was used for instance to test for differences in HDRS improvement dependent on genotypes and for the DAT1 polymorphism, a predefined order of genotypes 9/949/10410/ 10 or 9/9 o9/10, o10/10 (two-sided) was used. Differences in frequencies of categorical variables such as gender or number of responders were analyzed using the w 2 test with Fisher exact test in small subgroups. After categorization of response to treatment into responders and nonresponders, the effect size was calculated as cross-product (odds ratio (OR)). The variance of the natural logarithm of the ORs, var(ln(OR)), was calculated as sum of (1/n) of the four groups, and the confidence limits of the natural logarithm of the OR were then calculated as ln(OR)71.96 ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi ðvarianceðlnðORÞÞÞ p and finally transformed back by exponentiation. 24 In order to explore joint effect, confounding or effect modification between the different clinical predictors of response we performed logistic regression analysis. These analyses included age (categorized into younger than 30 years, between 30 and 50, and older than 50 years), gender, number of previous depressive episodes (categorized into none, between 1 and 3, and more than 3), number of manic episodes, initial severity of the depressive episode (categorized into HDRS score o18, and 418), the hospitals (3 centers), and the SERT and DAT1 genotype. Stepwise deletion of those parameters with the smallest contribution to the predicton of response was used and only those parameters with an at least marginally significant effect (Po0.15 according to Wald statistics) are presented. All statistical analyses were performed using the SPSS statistical software version 11 (SPSS Inc., Chicago, USA).
Results
A total of 264 patients were hospitalized for an acute episode of major depression and were included in this study after having given informed consent. Only 190 of them, 67 men and 123 women, could be fully assessed. Their mean time in hospital was 58 days, with a standard deviation of 40 days. Most of them (n ¼ 159) were finally discharged, and the others were transferred to other departments.
The remaining 74 patients dropped out before day 21 because they were discharged (n ¼ 46) or discharged themselves (n ¼ 21), were transferred to another department (n ¼ 3), had committed suicide (n ¼ 3), or left because of unknown reasons (n ¼ 1).
Genotype frequencies and baseline severity of depression did not differ between fully assessed patients (n ¼ 190) and dropouts (n ¼ 74). Allele frequencies of the DAT1 3 0 VNTR polymorphism 9-repeat and 10-repeat alleles were 27 and 73%, respectively, in patients who completed the study, and 23 and 77%, respectively, in dropouts (difference not significant, Fisher's exact test). Mean baseline HDRS was 3078 in the fully assessed group and 3077.5 in the dropout group. There were 10 patients with HDRS scores between 7 and 18. When excluding these from the analysis, the significance of the DAT1 genotype for response was essentially the same (P ¼ 0.012). We kept those patients within the analysis, to make the analysis as far as possible reflecting the clinical reality of depression treatment.
In the following, we only analyzed the data of the 190 patients who completed the study. Their mean age was 46 years (range 19-72 years). Most of them (n ¼ 168) suffered from unipolar major depression and only a few (n ¼ 22) from bipolar depression with known manic episodes in their histories. Median (range) HDRS score was 31 (8-53) at baseline and 16 (0-41) on day 21. Response was defined as decrease in HDRS between baseline and day 21 and expressed in percent decrease. The mean decrease in HDRS was 44%, with a range between À50% (negative values indicating worsening of symptoms) and 100%. Mean decrease in HDRS did not significantly differ between patients with bipolar disorder and those with unipolar disorder, nor did it depend on gender (men: 47%731, women: 43%730), concomitant alcohol abuse, smoking, or age (spearman rank correlation analysis, r 2 o0.01 for all analyses). Forty-two percent of patients were early responders, that is, their HDRS scores improved by more than 50%.
Medication was not prescribed by the study protocol, rather, physicians were asked to prescribe as usual. Table 1 gives the most frequently administered drugs: mirtazapine (n ¼ 58), SSRIs (total n ¼ 77; with sertraline (n ¼ 15), citalopram (n ¼ 37), paroxetine (n ¼ 16), fluvoxamine (n ¼ 1), and fluoxetine (n ¼ 8), venlafaxine (n ¼ 39) and tricyclic antidepressants (total n ¼ 37; with amitriptyline (n ¼ 16), clomipramine (n ¼ 2), doxepin (n ¼ 14), and trimipramine (n ¼ 5)). The remaining antidepressant drugs were classified as 'others' (reboxetine n ¼ 7, nefazodone n ¼ 1, moclobemide n ¼ 1, mianserin n ¼ 1, St John's Wort n ¼ 1). There was no significant difference in improvement between the five major groups formed according to types of antidepressant medication (Table 1) .
Some patients switched to another medication during the observation period. In these cases, all drugs that had been administered within the week prior to HDRS rating were included into our analysis since they might have contributed to the therapeutic effect. For these patients, two drugs are listed and they are not discriminated from those patients who received antidepressant combinations. In the subgroup of patients receiving two drugs (n ¼ 28) or three drugs (n ¼ 2), mean decline in HDRS (45%730) did not differ from that in-patient receiving one drug (41%733).
Frequencies of the dopamine transporter DAT1 3 0 VNTR repeat genotypes were 54.5% for the 10/10-repeat genotype, 37.0% for the 9/10-repeat genotype, and 8.5% for the 9/9-repeat genotype. These DAT1 genotype frequencies were not significantly different from Hardy-Weinberg equilibrium. One patient was a heterozygous carrier of the 8-repeat allele with an 8/10-repeat genotype; this patient was a full responder (with decline in HDRS from 18 on day 3 to 1 on day 21) to antidepressant treatment but was excluded from further analysis. Other alleles with 6, 7, or 12 repeats have been described earlier but were not found in our sample. Frequencies of SERT genotypes were 36% homozygous carriers of the long allele (l/l), 48% heterozygotes (l/s) and 16% homozygous carriers of the short allele (s/s). SERT allele frequencies were also in Hardy-Weinberg equilibrium.
There was no gender difference in allelic distribution of the 9-and 10-repeat alleles, or in the distribution of the SERT short and long alleles. Since DAT1 has been reported to be related to substance abuse, we analyzed smoking and alcohol habits but found no association to DAT1 genotypes. Baseline severity of depression measured at hospital admission, number of previous depressive episodes, and ratio between bipolar and monopolar disorder did not differ between DAT1 and SERT genotype groups.
It was the primary aim of this pharmacogenetic analysis to study, how improvement of depression might differ between the studied DAT1 and SERT genotypes to the entire group of 190 patients. Medians of percent improvement in HDRS were 52% in the DAT1 genotype 10/10, 40% in genotype 10/ 9, and 35% in genotype 9/9 (P ¼ 0.013 according to the Jonckheere-Terpstra trend test). Parametric statistical analysis revealed a linear relationship between number of 9-repeat alleles with means (standard error of the mean) of 49% (3%), 41% (3%), 32% (8%) improvement in groups with the 10/10, 10/9, and 9/9 genotypes (P ¼ 0.016 according to linear regression analysis). The same trend of better improvement in carriers of the DAT1 10-repeat allele compared with the 9-repeat allele was found in male and female patients, in each of the three participating hospitals, in incident (1st episode) versus recurrent cases and in carriers of the 3 SERT 5 0 44 bp insertion/deletion polymorphism genotypes.
The effect of the DAT1 genotype on response was also independent of the specific class of drug used. However, a subgroup analysis taking into account the five groups of therapeutic agents (mitrazapine, SSRIs, tricyclics, venlafaxine, others) revealed the most prominent influence of the DAT1 genotype in the SSRI group (n ¼ 77) with median declines in HDRS of 54% (10/10), 31% (9/10), and 35% (9/9) (P ¼ 0.026, Jonckheere-Terpstra trend test). For mirtazapine (n ¼ 58), median declines in HDRS were 44% in 10/10 genotype carriers, 42% in 9/10 genotype carriers, and 33% in 9/9 genotype carriers (not statistically significant within this subgroup). Within the group of patients taking tricyclic antidepressants (n ¼ 37), carriers of the 10-repeat allele showed the same trend towards better response (63% in 10/10 carriers, 43% in 9/10 carriers, and 22% in 9/9 carriers; not significant). In Table 1 , the median responses are shown for each DAT genotype.
There were no differences in allele frequencies of the DAT1 genotypes between patients taking antidepressant combinations (who might be difficult-to-treat) and those on monotherapy. Total number exceeds number of subjects included in this study since those having received more than one antidepressant from different classes were counted separately for each drug. There was no statistically significant difference in any of the parameters between the antidepressant treatment groups (Kruskal-Wallis test). Abbreviations: HDRS, Hamilton Depression Rating Scale; SSRI, selective serotonin reuptake inhibitors. All data given as median (range) unless noted otherwise.
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When categorically defining response as a more than 50% decrease in the HDRS score 22, there was a significantly smaller number of responders among homozygous carriers of the DAT1 9-repeat allele than among heterozygous and homozygous carriers of the 10-repeat allele (19 versus 37 and 52%, respectively; P ¼ 0.0037, w 2 test for trend). For the calculation of the crude OR for non-response, the apparently best responding group, namely the carriers of the DAT1 genotype 10/10, were considered as the reference group (OR by definition equal to unity) and compared with this group, the 9/10 carriers had an OR of 1.9 (95% CI: 1.0-3.5) for the risk of non-response and in carriers of the 9/9 genotype versus the 10/10 genotype, the 9/9 carriers had an OR of even 4.8 (95% CI: 1.3-18).
As illustrated in Figure 1 , the effect of DAT1 genotype on the percent of responders was independent from type of medication.
Analysis of patients with unipolar and bipolar depression might indicate that the DAT1 polymorphism may have a different effect in patients with bipolar type depression, but numbers with this disease were too small to draw any final conclusions. In patients with unipolar major depression (n ¼ 168), there were 54% (n ¼ 49), 37% (n ¼ 23), and 21% (n ¼ 3) of responders among carriers of the DAT1 10/10, 9/10, and 9/9 genotypes, respectively, compared to 33% (n ¼ 5), 43% (n ¼ 3), and 0%, respectively, in patients with bipolar depression.
By logistic regression analysis, only the parameters hospital and DAT1 genotype turned out to be significant predictors of therapeutic response (P ¼ 0.02 for DAT and P ¼ 0.003 for hospital according to Wald statistics). Gender and number of previous depressive episodes were predictors of response only with marginal statistical significance (P ¼ 0.08 for gender and 0.15 for number of previous depressive episodes). The numbers of patients the three hospital centres were recruiting was 112 for hospital one, 22 for hospital two and 19 for hospital three. Was also tested for statistical interactions between DAT1 genotype and hospital, gender, number of previous episodes, and SERT genotype, but there was no significant interaction. In other words, the effect of DAT1 genotype on response showed exactly the same trend in the three hospitals, in both genders, in incident versus recurrent patients, and in the 3 SERT genotypes. The DAT genotype effect on response was significant also when analysed for the subgroup of patients in hospital one, only. The OR calculated by logistic regression analysis are presented in Table 2 . These OR differ only marginally from the crude OR given above.
The relationship between response to treatment with the different classes of antidepressant drugs and the genotype of the high-affinity SERT is illustrated in Figure 2 . In the entire study sample, there were 46, 43 and 43% responders in the SERT l/l, l/s, and s/s genotype groups, respectively. Neither for the entire study sample nor for the subgroups according to antidepressant medication there was a statistically significant relationship between response and SERT genotype. Nevertheless, it is notable that among patients taking SSRIs response was higher in carriers of one or two long alleles. Carriers of the SERT 5 0 s/s-genotype had a lower rate of responders (27%) compared to carriers of the s/l and l/l genotype (47%). Median % improvement in HDRS score was 37% in homozygous carriers of the s-allele and 45% in l/l, s/l genotype carriers.
Discussion
More than one-third of all patients do not satisfactorily respond to their first-line antidepressant drug therapy. 25 Genetic variability might explain part of the variability in therapeutic outcome and adverse drug effects. The DAT1 3 0 UTR 40-bp VNTR polymorphism has been subject of many studies on various diseases, including bipolar affective disorders. 12, 13 Antidepressant drugs, in particular SSRIs, modulate dopamine transporter availability, and dopaminergic mechanisms may play an important role in antidepressant drug action. [8] [9] [10] 26, 27 However, according to our best knowledge, the relationship between the DAT1 polymorphism and antidepressant response has not been studied.
Our study was carried out in a naturalistic setting. The study protocol did not prescribe a specific antidepressant agent. This might have impaired the statistical power of our analysis, but our comparatively unselected sample has the advantage of being closer to daily psychiatric reality. Of course, this procedure reduces power compared with a larger study with one mediation and one dose scheme only, but when planning this study we anticipated that strong predictors might nevertheless come out. In this study, we found that the 9-repeat allele of the dopamine transporter DAT1 was associated with significantly poorer response compared to the 10-repeat allele. This was found consistently for all types of antidepressants used in the study and there was a gene-dose-like trend, that is, response was lowest in homozygous carriers of the 9-repeat allele, higher in the heterozygotes and highest in carriers of zero 9-repeat alleles. However, this result still requires further experimental and clinical confirmation particularly since the power of our study was not optimal to prove the finding and since the functional role of this polymorphism in different regions of the human brain is not fully clear.
Interestingly enough, the effect of the DAT1 polymorphism was not limited to a particular class of medication but was found in SSRI treatment, in treatment with mirtazapine, with venlafaxine, and with tricyclics ( Figure 1 ). Similar observations of resembling biological reactions after treatment with even very different classes of drugs were made by others and reflect the general experience that antidepressant response may not be drug-specific but linked to a common final pathway to which different drugs with their various sites of action contribute. 28 Indeed, polymorphisms in molecules downstream of direct drug targets are not likely to modulate only a single drug's action, and drug classes as different as SSRI and norepinephrine reuptake inhibitors may share common beneficial effects on synaptic plasticity. 29 In many clinical trials, evaluation of therapeutic response is performed over the initial 6 weeks of treatment with one medication. Again this is a highly artificial setting. In clinical routine, one would mostly switch the mediation or at a second drug at latest after 2 or 3 weeks of unsuccessful treatment. Therefore, we were particularly interested in the rapid response to antidepressant drugs as decline in HDRS already after 3 weeks. This relatively early evaluation seems also more appropriate since it must be the primary goal to administer an individually optimized drug treatment right from the beginning. Besides, an excellent correlation has been found between early response and final outcome. [30] [31] [32] [33] In our study, 42% of participants met the response criterion already after a 3-week treatment. Mean decrease in HDRS was 44% at that time. Eighteen patients did not show any amelioration or even worsening of symptoms. In a pharmacogenetic study in MexicanAmerican outpatients with depression, mean decrease in HDRS was about 30% after 3 weeks of treatment with either fluoxetine or desipramine. 21 In a similar study on the catechol-O-methyltransferase Val/Met polymorphism in patients treated with mirtazapine, patients had a mean decrease in HDRS-17 score of 38% after 3 weeks, 32 which is similar to our results. These comparisons show that our sample is a typical sample of moderately to severely depressed patients.
Allele frequencies of the 9-repeat and 10-repeat alleles of the DAT1 gene were in Hardy-Weinberg equilibrium in our cohort of depressed patients and did not differ from those observed in healthy Caucasians. 34 Baseline severity of depression did not depend on DAT1 genotypes. This corresponds to the results of others 11, [35] [36] [37] [38] [39] who could not corroborate earlier findings suggesting an association of variants within the dopamine transporter gene with depression. 13, 40 However, response to antidepressant treatment correlated positively with the number of DAT1 10-repeat alleles in a gene-dose-like manner. Carriers of the 10-repeat allele were found to have increased expression levels of DAT1.
14 Possibly dopamine transport function plays a crucial role in antidepressant response. Increased binding to the dopamine transporter was observed in healthy volunteers following repeated SSRIs administration. 9 How dopamine transport in the human brain really correlates with antidepressant response has still to been elucidated. Dopamine transporter affinity in the basal ganglia of depressed untreated patients was reported to be higher than normal. 7 Considering the potential impact of the dopaminergic system in depression, it might have been rational to include also genetic variants in dopamine receptors into our evaluation. We did not do this since polymorphisms in the dopamine D2 receptor are still of equivocal functional relevance and the dopamine D3 and D4 polymorphisms, which do result in functional amino-acid substitutions, were correlated earlier with the response to antidepressant treatment but no strong correlations were found. 41 The lack of clinical predictors for antidepressant drug response strengthens the need to find individual molecular phenotypes for drug response. There is some evidence that the SERT 44-bp insertion/deletion polymorphism participates in the modulation of SSRI response (for a review see Kirchheiner et al. 1 and Murphy et al. 42 ). The effect, however, seems to be small and was mainly seen in patients treated with SSRIs. 42 In an analysis summarizing all previous studies (sample size n ¼ 974), carriers of at least one long allele had an OR of 1.7 for being a responder. 1 We included the SERT polymorphism as a covariate in our analysis and, in our entire sample, the OR to respond was 1.03 (95% CI between 0.47 and 2.3) for carriers of at least one long allele (l/l, s/l) versus homozygous carriers of the short allele (ss); thus, there was not any effect of the SERT polymorphism on response. However, in our study, patients took different medications, and only 77 of all patients received SSRIs. Within the group of patients receiving SSRI treatment, the relative chance to respond was higher for carriers of one or two long alleles with 2.4 (0.6-10, 95% CI) supporting the concept that SERT s/s genotype carriers have a lower response rate to SSRIs. 2 The allele frequency of the long allele of the SERT 44 bp polymorphism did not differ from the frequency observed in other healthy Caucasian (60% (95% CI 54-66%) in our study versus 58% (95% CI 56-63% in healthy Italians) 43 or other healthy Germans. 44 In other populations, different allele frequencies are described 45 but this difference is due to relevant differences between the major ethnic groups, Africans, Asians, and Caucasians and in our study, only Caucasians were included.
Earlier studies indicated that the SERT polymorphism may be a useful predictors for the response to SSRIs and the the norepinephrine transporter genotype may be involved in response to antidepressant acting on the noradrenergic system. 46 Thus, it seemed obvious to test whether the dopamine transporter as well modifies the response to antidepressant treatment. This exploratory study might be a first hint that response to antidepressant drug treatment might be affected by a VNTR polymorphism in the gene coding for the dopamine transporter DAT1. Optimally, the study might have even been larger, but post hoc power analysis comparing the rate of responders in carriers of one or two DAT1 9-repeat alleles (n ¼ 86) to that of homozygous wild-types (n ¼ 103) with 34% responders versus 52% (for a sample size of n ¼ 86 for both groups, p alpha ¼ 0.016, exact Fisher test) resulted in a power of 60%; this confirms that the study was not too small to be reliable. Slower improvement of depression during therapy in carriers of the 9-repeat allele might reflect differences in dopamine transport function. Although the functional role of the studied DAT1 polymorphism is not fully understood notably also in another clinical study in Parkinson's patients the DAT1 polymorphism was -among several polymorphisms tested in several gene of the dopaminergic system -the only polymorphism that was significantly associated with adverse psychiatric and neurologic effects of D-dopa therapy. 19 These findings suggest further studies to find out how the VNTR effects DAT1 expression in different areas of the human brain and how dopamine transport may be involved in the response to antidepressants.
